ACCME defers a ban on logos again

Share this article:
ACCME defers a ban on logos again
Samuel: ACCME should follow CME Coalition’s logo policies

The ACCME said its board decided, after a wave of feedback, to defer a ban on use of corporate logos in educational materials, disclosures and acknowledgement of commercial support. It's the second time in three years that the ACCME board punted on the ban.

The accreditor began accepting public comments on the proposed prohibition in December. By the time the comment period closed January 31, the ACCME had received responses from 227 people, about a third of which opposed the change.

However, those in favor of holding onto logos included organizations representing thousands of members. The Council of Medical Specialty Societies (CMSS), with 39 member societies representing 750,000 physicians in the US, said removing logos could be “counterproductive,” wrote CMSS's EVP/CEO, Norman Kahn, MD.

Deborah Samuel, MBA, president of the Society for Academic CME (SACME), noted that the ACCME position should reflect the principles outlined in the CME Coalition's Responsible Logo Use Guidelines.

The proposal was tabled “pending further discussion,” the accreditor said, a move cheered by some in the CME community. “The CME Coalition applauds the ACCME for the deliberative and thoughtful way that it's approaching this issue,” said Andy Rosenberg, senior advisor to the coalition.

Those who agreed with the changes told the ACCME that banning logos would minimize any possibility of conflict of interest, eliminate ambiguity, and decrease participants' perception of real or perceived bias. Those opposed said that the current standards were sufficient.

Outlawing logos would have required changes to the ­ACCME's Standards for Commercial Support.

The board did adopt changes to simplify the accreditation requirements and process, including removing some of the accreditation criteria and policy requirements and streamlining the process of applying for initial accreditation.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?